[1] L. Yang, J. Wang, J. Cheng, Y, et al.Quality assurance target for community-based breast cancer screening in China: a model simulation, BMC cancer, 2018;18: 261.
[2] D.J. Slamon, M.D, D. Ph., B. Leylandjones, M.D, et al.Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, N Engl J Med, 2001;344 : 783-792.
[3] S.D. Russell, K.L. Blackwell, J. Lawrence, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials, Journal of clinical oncology.2010;28: 3416-3421.
[4] N. Robert, B. Leyland-Jones, L. Asmar,et al.Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer, Journal of clinical oncology:official journal of the American Society of Clinical Oncology, 2006;24:2786-2792.
[5] S.D. Russell, K.L. Blackwell, J. Lawrence, et al.Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National surgical adjuvant breast and bowel project B-31 and the North central cancer treatment group N9831 clinical trials, J. Clin. Oncol,2010;28:3416-3421.
[6] M. Procter, T.M. Suter, E. de Azambuja,et al.Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial, J. Clin. Oncol,2010;28: 3422-3428.
[7] V. Valero, J. Forbes, M.D. Pegram, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens, J. Clin. Oncol, 2011;29: 149-156.
[8] D. Slamon, W. Eiermann, N. Robert, et al.Breast Cancer International Research Group, Adjuvant trastuzumab in HER2-positive breast cancer, N. Engl. J. Med. Econ, 2011;365:1273-1283.
[9] A. Donahue, J.S. Mccune, S. Faucette, et al.Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing, Cancer Chemother. Pharmacol,2001: 47:373-379.
[10] V. Diaby, A.A. Ali, G. Adunlin, et al. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients, Curr. Med. Res. Opin,2016; 32:991-996.
[11] P.K. Petrou, M.A. Talias, Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus, Expert. Rev. Pharmacoecon Outcomes Res, 2014;14:131-138.
[12] T. Purmonen, J.A. Martikainen, E.J. Soini, et al.Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland, Clin. Ther, 2008;30:382.
[13] S. Ward, E. Simpson, S. Davis, et al.Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation, Health Technol. Assess,2007; 11:1-144.
[14] E.H. Romond, E.A. Perez, J. Bryant, et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, The New England journal of medicine, 2005;353:1673-1684.
[15] M. Untch, P.A. Fasching, G.E. Konecny,et al.Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J. Clin. Oncol,2011;29:3351-3357.
[16]P. Jitawatanarat, T.L. O'Connor, E.B. Kossoff,et al.Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer, J. Breast Cancer, 2014;17:356-362.
[17]P.A. Ganz, E.H. Romond, R.S. Cecchini,et al. Mamounas, N. Wolmark, Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2, J. Clin. Oncol,2017; 35:3942-3948.
[18] C. Dang, N. Lin, B. Moy, et al.Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea, J. Clin. Oncol,2010;28:2982-2988.
[19] S. Bayraktar, A.M. Gonzalez-Angulo, X. Lei,et al.Meric-Bernstam, Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer, Cancer, 2012;118:2385-2393.
[20] W. Chen, J. He, S. Song, et al.Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer, Oncol. Lett,2015; 9:1922-1926.
[21] H.C. Kolberg, L. Akpolat-Basci, M. Stephanou,et al.Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years, Breast care, 2016;11:323-327.
[22] I. Echavarria, M. Granja, C. Bueno, et al.Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer, Breast Cancer Res. Treat,2017;162:181-189.
[23] A. Tiwari, A. Gogia, S. Deo, et al.Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: an Indian experience, Indian J. Cancer, 2017;54:343-346.
[24] I.C. Henderson, D.A. Berry, G.D. Demetri,et al.Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer, J. Clin. Oncol,2003; 21:976.
[25] J. Caron, A. Nohria, Cardiac toxicity from breast cancer treatment: can we avoid this?, Curr. Oncol. Rep,2018;20:61.
[26] S.M. Swain, F.S. Whaley, M.S. Ewer.Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials, Cancer, 2003;97:2869-2879.
[27]S.M. Swain, F.S. Whaley, M.C. Gerber,et al.Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy, J. Clin. Oncol,1997;15:1333-1340.
[28] F. Shaikh, L.L. Dupuis, S. Alexander,et al.Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysis, J. Natl. Cancer Inst,2016; 108:djv357.
[29] E.A. Perez, E.H. Romond, V.J. Suman,et al.Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831, J. Clin. Oncol,2014;32:3744-3752.